Research Analysts Offer Predictions for ENTA Q2 Earnings

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) – Investment analysts at HC Wainwright boosted their Q2 2026 earnings per share (EPS) estimates for shares of Enanta Pharmaceuticals in a research report issued on Tuesday, February 10th. HC Wainwright analyst B. Folkes now anticipates that the biotechnology company will post earnings of ($0.51) per share for the quarter, up from their prior forecast of ($0.54). HC Wainwright has a “Buy” rating and a $20.00 price objective on the stock. The consensus estimate for Enanta Pharmaceuticals’ current full-year earnings is ($4.65) per share. HC Wainwright also issued estimates for Enanta Pharmaceuticals’ Q3 2026 earnings at ($0.51) EPS, Q4 2026 earnings at ($0.73) EPS, FY2027 earnings at ($2.53) EPS, FY2028 earnings at ($3.23) EPS, FY2029 earnings at ($2.40) EPS and FY2030 earnings at ($2.19) EPS.

Enanta Pharmaceuticals (NASDAQ:ENTA) last announced its earnings results on Monday, February 9th. The biotechnology company reported ($0.42) EPS for the quarter, beating analysts’ consensus estimates of ($0.54) by $0.12. Enanta Pharmaceuticals had a negative return on equity of 78.58% and a negative net margin of 106.80%.The company had revenue of $18.62 million during the quarter, compared to the consensus estimate of $16.14 million.

Other equities research analysts have also recently issued reports about the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Enanta Pharmaceuticals in a research report on Wednesday, January 21st. JPMorgan Chase & Co. assumed coverage on shares of Enanta Pharmaceuticals in a research note on Friday, November 14th. They set an “overweight” rating and a $17.00 target price on the stock. Six analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $20.33.

Enanta Pharmaceuticals Stock Up 0.1%

NASDAQ:ENTA opened at $13.85 on Thursday. The stock has a market cap of $401.93 million, a price-to-earnings ratio of -4.33 and a beta of 0.98. The company’s 50 day moving average price is $14.09 and its 200-day moving average price is $11.46. Enanta Pharmaceuticals has a 52 week low of $4.09 and a 52 week high of $17.15.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the business. Meeder Asset Management Inc. purchased a new position in Enanta Pharmaceuticals during the fourth quarter worth $32,000. Strs Ohio bought a new stake in shares of Enanta Pharmaceuticals in the 4th quarter worth about $50,000. Mirae Asset Global Investments Co. Ltd. lifted its holdings in shares of Enanta Pharmaceuticals by 333.9% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,584 shares of the biotechnology company’s stock worth $57,000 after acquiring an additional 2,758 shares during the last quarter. Quarry LP purchased a new position in shares of Enanta Pharmaceuticals during the 3rd quarter worth about $81,000. Finally, China Universal Asset Management Co. Ltd. grew its holdings in Enanta Pharmaceuticals by 103.8% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 8,747 shares of the biotechnology company’s stock valued at $105,000 after purchasing an additional 4,454 shares during the last quarter. Institutional investors own 94.99% of the company’s stock.

Insiders Place Their Bets

In other news, CEO Jay R. Luly sold 4,743 shares of the company’s stock in a transaction dated Friday, December 5th. The stock was sold at an average price of $14.23, for a total value of $67,492.89. Following the completion of the transaction, the chief executive officer owned 858,026 shares of the company’s stock, valued at $12,209,709.98. This represents a 0.55% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, insider Tara Lynn Kieffer sold 2,106 shares of the firm’s stock in a transaction on Friday, December 5th. The shares were sold at an average price of $14.23, for a total transaction of $29,968.38. Following the transaction, the insider directly owned 30,620 shares of the company’s stock, valued at $435,722.60. The trade was a 6.44% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 11,961 shares of company stock worth $170,149 over the last three months. 11.48% of the stock is currently owned by company insiders.

Key Enanta Pharmaceuticals News

Here are the key news stories impacting Enanta Pharmaceuticals this week:

• Positive Sentiment: Zacks upgraded ENTA to a Rank #2 (Buy), calling out improved earnings prospects — a catalyst that can drive near-term buying interest. What Makes Enanta Pharmaceuticals (ENTA) a New Buy Stock
• Positive Sentiment: HC Wainwright reiterated a “Buy” rating with a $20 price target, which supports upside expectations versus the current trading level and can attract momentum buyers. Enanta Pharmaceuticals’ (ENTA) Buy Rating Reiterated at HC Wainwright
• Positive Sentiment: HC Wainwright raised several forward-year EPS estimates (FY2027–FY2030 and quarters Q2/Q3 2026 modestly), indicating slightly improved longer-term profitability assumptions from the same analyst team. These upward tweaks, combined with the maintained Buy rating and $20 target, are constructive for sentiment. MarketBeat: Enanta – HC Wainwright Estimate Changes
• Neutral Sentiment: Reports show a large “increase” in short interest but the data reads as 0 shares with NaN changes and a 0.0 days short-interest ratio — likely a reporting anomaly and not an active short-selling signal. Investors should treat this as non-informative until clarified.
• Negative Sentiment: HC Wainwright lowered its Q4 2026 EPS estimate to ($0.73) from ($0.56), a near-term earnings deterioration that could weigh on sentiment for the upcoming quarter despite the firm’s overall Buy stance. MarketBeat: Enanta – HC Wainwright Lowers Q4 2026 Estimate

About Enanta Pharmaceuticals

Enanta Pharmaceuticals, Inc is a biotechnology company headquartered in Watertown, Massachusetts, specializing in the discovery and development of novel, small-molecule drugs targeting viral diseases. Leveraging a proprietary chemistry platform, Enanta has built extensive expertise in designing potent inhibitors of viral proteases and polymerases. The company initially gained recognition through partnerships focused on hepatitis C virus (HCV), where its protease inhibitors formed a key component of ABBVIE’s direct‐acting antiviral regimens.

Building on its HCV experience, Enanta has expanded its pipeline to address respiratory syncytial virus (RSV) and other viral infections.